Patient and health provider costs of integrated HIV, diabetes and hypertension ambulatory health services in low-income settings - an empirical socio-economic cohort study in Tanzania and Uganda.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
10 09 2021
Historique:
received: 15 02 2021
accepted: 11 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 16 10 2021
Statut: epublish

Résumé

Integration of health services might be an efficient strategy for managing multiple chronic conditions in sub-Saharan Africa, considering the scope of treatments and synergies in service delivery. Proven to promote compliance, integration may lead to increased economies-of-scale. However, evidence on the socio-economic consequences of integration for providers and patients is lacking. We assessed the clinical resource use, staff time, relative service efficiency and overall societal costs associated with integrating HIV, diabetes and hypertension services in single one-stop clinics where persons with one or more of these conditions were managed. 2273 participants living with HIV infection, diabetes, or hypertension or combinations of these conditions were enrolled in 10 primary health facilities in Tanzania and Uganda and followed-up for up to 12 months. We collected data on resources used from all participants and on out-of-pocket costs in a sub-sample of 1531 participants, while a facility-level costing study was conducted at each facility. Health worker time per participant was assessed in a time-motion morbidity-stratified study among 228 participants. The mean health service cost per month and out-of-pocket costs per participant visit were calculated in 2020 US$ prices. Nested bootstrapping from these samples accounted for uncertainties. A data envelopment approach was used to benchmark the efficiency of the integrated services. Last, we estimated the budgetary consequences of integration, based on prevalence-based projections until 2025, for both country populations. Their average retention after 1 year service follow-up was 1911/2273 (84.1%). Five hundred and eighty-two of 2273 (25.6%) participants had two or all three chronic conditions and 1691/2273 (74.4%) had a single condition. During the study, 84/2239 (3.8%) participants acquired a second or third condition. The mean service costs per month of managing two conditions in a single participant were $39.11 (95% CI 33.99, 44.33), $32.18 (95% CI 30.35, 34.07) and $22.65 (95% CI 21.86, 23.43) for the combinations of HIV and diabetes and of HIV and hypertension, diabetes and hypertension, respectively. These costs were 34.4% (95% CI 17.9%, 41.9%) lower as compared to managing any two conditions separately in two different participants. The cost of managing an individual with all three conditions was 48.8% (95% CI 42.1%, 55.3%) lower as compared to managing these conditions separately. Out-of-pocket healthcare expenditure per participant per visit was $7.33 (95% CI 3.70, 15.86). This constituted 23.4% (95% CI 9.9, 54.3) of the total monthly service expenditure per patient and 11.7% (95% CI 7.3, 22.1) of their individual total household income. The integrated clinics' mean efficiency benchmark score was 0.86 (range 0.30-1.00) suggesting undercapacity that could serve more participants without compromising quality of care. The estimated budgetary consequences of managing multi-morbidity in these types of integrated clinics is likely to increase by 21.5% (range 19.2-23.4%) in the next 5 years, including substantial savings of 21.6% on the provision of integrated care for vulnerable patients with multi-morbidities. Integration of HIV services with diabetes and hypertension control reduces both health service and household costs, substantially. It is likely an efficient and equitable way to address the increasing burden of financially vulnerable households among Africa's ageing populations. Additional economic evidence is needed from longer-term larger-scale implementation studies to compare extended integrated care packages directly simultaneously with evidence on sustained clinical outcomes.

Sections du résumé

BACKGROUND
Integration of health services might be an efficient strategy for managing multiple chronic conditions in sub-Saharan Africa, considering the scope of treatments and synergies in service delivery. Proven to promote compliance, integration may lead to increased economies-of-scale. However, evidence on the socio-economic consequences of integration for providers and patients is lacking. We assessed the clinical resource use, staff time, relative service efficiency and overall societal costs associated with integrating HIV, diabetes and hypertension services in single one-stop clinics where persons with one or more of these conditions were managed.
METHODS
2273 participants living with HIV infection, diabetes, or hypertension or combinations of these conditions were enrolled in 10 primary health facilities in Tanzania and Uganda and followed-up for up to 12 months. We collected data on resources used from all participants and on out-of-pocket costs in a sub-sample of 1531 participants, while a facility-level costing study was conducted at each facility. Health worker time per participant was assessed in a time-motion morbidity-stratified study among 228 participants. The mean health service cost per month and out-of-pocket costs per participant visit were calculated in 2020 US$ prices. Nested bootstrapping from these samples accounted for uncertainties. A data envelopment approach was used to benchmark the efficiency of the integrated services. Last, we estimated the budgetary consequences of integration, based on prevalence-based projections until 2025, for both country populations.
RESULTS
Their average retention after 1 year service follow-up was 1911/2273 (84.1%). Five hundred and eighty-two of 2273 (25.6%) participants had two or all three chronic conditions and 1691/2273 (74.4%) had a single condition. During the study, 84/2239 (3.8%) participants acquired a second or third condition. The mean service costs per month of managing two conditions in a single participant were $39.11 (95% CI 33.99, 44.33), $32.18 (95% CI 30.35, 34.07) and $22.65 (95% CI 21.86, 23.43) for the combinations of HIV and diabetes and of HIV and hypertension, diabetes and hypertension, respectively. These costs were 34.4% (95% CI 17.9%, 41.9%) lower as compared to managing any two conditions separately in two different participants. The cost of managing an individual with all three conditions was 48.8% (95% CI 42.1%, 55.3%) lower as compared to managing these conditions separately. Out-of-pocket healthcare expenditure per participant per visit was $7.33 (95% CI 3.70, 15.86). This constituted 23.4% (95% CI 9.9, 54.3) of the total monthly service expenditure per patient and 11.7% (95% CI 7.3, 22.1) of their individual total household income. The integrated clinics' mean efficiency benchmark score was 0.86 (range 0.30-1.00) suggesting undercapacity that could serve more participants without compromising quality of care. The estimated budgetary consequences of managing multi-morbidity in these types of integrated clinics is likely to increase by 21.5% (range 19.2-23.4%) in the next 5 years, including substantial savings of 21.6% on the provision of integrated care for vulnerable patients with multi-morbidities.
CONCLUSION
Integration of HIV services with diabetes and hypertension control reduces both health service and household costs, substantially. It is likely an efficient and equitable way to address the increasing burden of financially vulnerable households among Africa's ageing populations. Additional economic evidence is needed from longer-term larger-scale implementation studies to compare extended integrated care packages directly simultaneously with evidence on sustained clinical outcomes.

Identifiants

pubmed: 34503496
doi: 10.1186/s12916-021-02094-2
pii: 10.1186/s12916-021-02094-2
pmc: PMC8431904
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

230

Informations de copyright

© 2021. The Author(s).

Références

Glob Heart. 2017 Jun;12(2):81-90
pubmed: 28302553
Global Health. 2018 Jan 16;14(1):3
pubmed: 29338746
Nat Rev Cardiol. 2017 May;14(5):273-293
pubmed: 28230175
Prim Care Diabetes. 2009 Aug;3(3):181-8
pubmed: 19748331
Lancet. 2018 May 19;391(10134):2036-2046
pubmed: 29627160
BMJ Open. 2020 Jan 12;10(1):e031924
pubmed: 31932390
BMJ Glob Health. 2020 Jul;5(7):
pubmed: 32636311
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667
pubmed: 28688818
Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:107-11
pubmed: 22271734
Intern Emerg Med. 2016 Apr;11(3):299-305
pubmed: 27001886
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD003318
pubmed: 21735392
Med Care. 2005 Jul;43(7 Suppl):5-14
pubmed: 16056003
Lancet. 2010 Nov 20;376(9754):1785-97
pubmed: 21074253
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
BMJ Open. 2019 Apr 1;9(4):e026288
pubmed: 30940760
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Global Health. 2012 Jun 11;8:14
pubmed: 22686126
PLoS One. 2018 Mar 28;13(3):e0194047
pubmed: 29590150
Stat Med. 2000 Dec 15;19(23):3219-36
pubmed: 11113956
S Afr Med J. 1974 Mar 13;48(12):485-98
pubmed: 4821952
Cost Eff Resour Alloc. 2019 Aug 6;17:17
pubmed: 31406487
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Int J Health Sci (Qassim). 2016 Apr;10(2):219-28
pubmed: 27103904
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
Trop Med Int Health. 2011 Oct;16(10):1276-84
pubmed: 21733046
BMJ Open. 2020 Oct 7;10(10):e039237
pubmed: 33033029
BMC Health Serv Res. 2010 Dec 14;10:339
pubmed: 21144064
Int J Equity Health. 2019 Feb 28;18(1):38
pubmed: 30819193
AIDS. 2018 Sep 24;32(15):2179-2188
pubmed: 30134294
J Clin Epidemiol. 2014 Mar;67(3):254-66
pubmed: 24472295

Auteurs

Tinevimbo Shiri (T)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Josephine Birungi (J)

The AIDS Support Organisation, Mulago Hospital Complex, Kampala, Uganda.
Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.

Anupam V Garrib (AV)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Sokoine L Kivuyo (SL)

National Institutes for Medical Research, Dar es Salaam, Tanzania.

Ivan Namakoola (I)

Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.

Janneth Mghamba (J)

Directors Office, Ministry of Health, Community Development, Gender, Elderly and Children, Kampala, Uganda.

Joshua Musinguzi (J)

Directors Office, Ministry of Health, Community Development, Gender, Elderly and Children, Kampala, Uganda.

Godfather Kimaro (G)

School of Public Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Gerald Mutungi (G)

Non-Communicable Diseases Control Programme, Ministry of Health, Kampala, Uganda.

Moffat J Nyirenda (MJ)

The AIDS Support Organisation, Mulago Hospital Complex, Kampala, Uganda.
London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.

Joseph Okebe (J)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Kaushik Ramaiya (K)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
Hindu Mandal Hospital, Dar es Salaam, Tanzania.

M Bachmann (M)

Norwich Medical School, University of East Anglia, Norwich, UK.

Nelson K Sewankambo (NK)

Makerere University College of Health Sciences, Kampala, Uganda.

Sayoki Mfinanga (S)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
National Institutes for Medical Research, Dar es Salaam, Tanzania.
School of Public Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Shabbar Jaffar (S)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

Louis W Niessen (LW)

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. louis.niessen@lstmed.ac.uk.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. louis.niessen@lstmed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH